5.54
-0.2075(-3.61%)
Currency In USD
| Previous Close | 5.75 |
| Open | 5.8 |
| Day High | 5.94 |
| Day Low | 5.54 |
| 52-Week High | 14.57 |
| 52-Week Low | 3.81 |
| Volume | 1,991 |
| Average Volume | 10,924 |
| Market Cap | 55.2M |
| PE | -3.67 |
| EPS | -1.51 |
| Moving Average 50 Days | 5.11 |
| Moving Average 200 Days | 5.96 |
| Change | -0.21 |
If you invested $1000 in Serina Therapeutics Inc (SER) since IPO date, it would be worth $57.21 as of May 09, 2025 at a share price of $5.538. Whereas If you bought $1000 worth of Serina Therapeutics Inc (SER) shares 5 years ago, it would be worth $204.05 as of May 09, 2025 at a share price of $5.538.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Serina Therapeutics to Present at JonesResearch Virtual CNS Day
GlobeNewswire Inc.
Apr 29, 2025 10:00 AM GMT
HUNTSVILLE, AL, April 29, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, announced that Steve Ledger,
Serina Therapeutics to Present at the 4th LNP Formulation & Process Development Summit
GlobeNewswire Inc.
Apr 15, 2025 10:30 AM GMT
HUNTSVILLE, AL, April 15, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, announced that Randall Morea
Serina Therapeutics Secures $5 Million in Funding to Support Advancement of SER-252 into Clinical Development in Advanced Parkinson's Disease
GlobeNewswire Inc.
Apr 08, 2025 8:30 PM GMT
HUNTSVILLE, Ala., April 08, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, today announced the closin